Original articleIncidence and Growth of Geographic Atrophy during 5 Years of Comparison of Age-Related Macular Degeneration Treatments Trials
Section snippets
Methods
The CATT participants and methods have been described in previous reports.2, 3, 4, 5, 6, 7 There were 1185 participants in the CATT who had AMD and untreated CNV or retinal neovascularization in the study eye. Participants were enrolled in 43 clinical centers in the United States between February 2008 and December 2009. Inclusion criteria have been described.4, 6 Participants at baseline had neovascularization or sequelae of neovascularization in the fovea and visual acuity between 20/25 and
Results
Among 1185 participants, 1183 had evaluable photographs at baseline, 1061 at year 1, 1012 at year 2, and 517 at year 5. Of these, 81 had GA at baseline, 122 developed GA during year 1, 42 developed GA during year 2, and 102 developed GA between the year 2 and the year 5 visit (Fig 1). Among the participants with GA, growth of GA could be determined from 2 or more visits in 81 prevalent cases and in 114 cases in which GA was detected at year 1 and 19 at year 2.
Discussion
Our study identified a number of risk factors for the development of GA in exudative AMD treated with anti–vascular endothelial growth factor (VEGF) therapy for up to 5 years. Among them are age, elevated cholesterol, ranibizumab treatment, poor vision, large total CNV lesion, RAP lesions, fellow eye GA, thinner subretinal tissue complex at the fovea and intraretinal fluid, especially in the fovea, and absence of subretinal fluid. Most of these factors had been identified in our previous report
References (30)
- et al.
Risk factors for the development of GA in CATT
Ophthalmology
(2014) - et al.
Growth of geographic atrophy in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT)
Ophthalmology
(2015) - et al.
Photographic assessment of baseline fundus morphologic features in the Comparison of Age-Related Macular Degeneration Treatments Trials
Ophthalmology
(2012) - et al.
Macular morphology and visual acuity in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT)
Ophthalmology
(2013) - et al.
Optical coherence tomography grading reproducibility during the Comparison of Age-Related Macular Degeneration Treatments Trials
Ophthalmology
(2012) - et al.
Pharmacogenetics for genes associated with age-related macular degeneration (AMD) in the Comparison of AMD Treatments Trials (CATT)
Ophthalmology
(2013) - et al.
Dietary Omega-3 fatty acids, other fat intake, genetic susceptibility, and progression to incident geographic atrophy
Ophthalmology
(2013) - et al.
Five year incidence, progression, and risk factors for age-related macular degeneration
Ophthalmology
(2014) - et al.
Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the Comparison of Age-Related Macular Degeneration Treatments Trials
Ophthalmology
(2016) - et al.
Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial
Lancet
(2013)
Seven-year outcomes in Ranibizumab-treated patients in ANCHOR, MARINA and HORIZON
Ophthalmology
Circularity index as a risk factor for progression of geographic atrophy
Ophthalmology
Systemic complement inhibition with eculizumab for geographic atrophy in age related macular degeneration. The COMPLETE Study
Ophthalmology
Incidence and progression of geographic atrophy: observations from a population-based cohort
Ophthalmology
The long-term natural history of geographic atrophy from age-related macular degeneration: enlargement of atrophy and implications for interventional clinical trials
Ophthalmology
Cited by (0)
∗Supplemental material is available at www.aaojournal.org.
Financial Disclosure(s): The author(s) have made the following disclosure(s): G-S.Y.: Consultant – Chengdu Kanghong Biotech Ltd.
G.J.J.: Consultant – Heidelberg Engineering, Neurotech, Alcon/Novartis, and Roche/Genentech.
C.A.T.: Research support – Genentech; Royalties – Alcon/Novartis.
M.G.M.: Consultant – Genentech/Roche.
Supported by Cooperative Agreements U10 EY023530, U10 EY017823, U10 EY017825, U10 EY017826, U10 EY017828, and R21EY023689 from the National Eye Institute, National Institutes of Health, Department of Health and Human Services. ClinicalTrials.gov identifier NCT00593450.
Author Contributions:
Conception and design: Grunwald, Pistilli, Daniel, Ying, Jaffe, Toth, Hagstrom, Maguire, Martin
Data collection: Grunwald, Pistilli, Daniel, Ying, Jaffe, Toth, Hagstrom, Maguire, Martin
Analysis and interpretation: Grunwald, Pistilli, Daniel, Ying, Pan, Jaffe, Toth, Hagstrom, Maguire, Martin
Obtained funding: Not applicable
Overall responsibility: Grunwald, Pistilli, Daniel, Ying, Pan, Jaffe, Toth, Hagstrom, Maguire, Martin
- ∗
Members of the Comparison of Age-Related Macular Degeneration Treatments Trials Research Group available online at www.aaojournal.org.